Marc  Tessier-Lavigne net worth and biography

Marc Tessier-Lavigne Biography and Net Worth

Director of Denali Therapeutics
Dr. Tessier-Lavigne was born in Trenton, Ontario, Canada. He received undergraduate degrees in physics from McGill University and in philosophy and physiology from Oxford University, where he was a Rhodes Scholar. He earned a Ph.D. in physiology from University College London (UCL) and performed postdoctoral work at UCL and at Columbia University. He then held faculty positions at the University of California, San Francisco (UCSF) and subsequently at Stanford University, where he was the Susan B. Ford Professor in the School of Humanities and Sciences. While at UCSF and Stanford he was also an investigator with the Howard Hughes Medical Institute.

A world leader in the study of brain development and repair, Dr. Tessier-Lavigne’s research has focused on the cause and treatment of degenerative brain diseases such as Alzheimer’s and Parkinson’s, as well as on therapies for spinal cord injuries. Dr. Tessier-Lavigne and his colleagues revealed how neural circuits in the brain form during embryonic development by identifying molecules that direct the formation of connections among nerve cells. Defects in these mechanisms lead to neurological disorders. These mechanisms also provide targets to assist regeneration of nerve connections after trauma. His contributions have been recognized by numerous prizes and honors, including his election as a Member of the National Academy of Sciences (USA), the National Academy of Medicine (USA), and the American Philosophical Society and as a Fellow of the Royal Society (UK), the Royal Society of Canada, the Academy of Medical Sciences (UK), the American Association for the Advancement of Science, and the American Academy of Arts and Sciences.

In 2003, Dr. Tessier-Lavigne was recruited to biotechnology company Genentech, where he became Executive Vice President for Research and Chief Scientific Officer, directing 1,400 scientists in disease research and drug discovery for cancer, immune disorders, infectious diseases, and neurodegenerative diseases, while maintaining an active research laboratory.

In 2011, Dr. Tessier-Lavigne became President of The Rockefeller University, a leading biomedical research university in New York City. At Rockefeller, Dr. Tessier-Lavigne worked with faculty, students, staff and trustees to develop and execute a nine-year strategic plan focused on junior and mid-career faculty recruitment; enhancement of graduate and postdoctoral education; establishment of interdisciplinary research programs and acquisition of advanced research instruments; expansion of the university’s translational medical infrastructure; and a $500 million, two-acre campus expansion project in the heart of Manhattan that broke ground in 2015.

Early in his tenure as Stanford president, Dr. Tessier-Lavigne, in partnership with Stanford Provost Persis Drell, launched a long-range planning process that led to the announcement of a new strategic vision for Stanford’s future in spring 2018. Built on more than 2,800 ideas received from across the Stanford community, the vision sets priorities across four areas: values, research, education and community. Now in its design phase, the long-range vision promises to chart a purposeful course for the university in its continued efforts to spark knowledge and creativity, advance learning, and accelerate impact for the benefit of humanity.

At a national and international level, Dr. Tessier-Lavigne has been an active spokesperson for societal support of science, through editorials, advocacy and congressional testimony.

Dr. Tessier-Lavigne serves on several scientific advisory, non-profit, and corporate boards. He has co-founded two start-up companies, targeting neurological disease and neurodegenerative disease.

What is Marc Tessier-Lavigne's net worth?

The estimated net worth of Marc Tessier-Lavigne is at least $38.38 million as of November 23rd, 2022. Dr. Tessier-Lavigne owns 1,870,356 shares of Denali Therapeutics stock worth more than $38,379,705 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Tessier-Lavigne may own. Additionally, Dr. Tessier-Lavigne receives an annual salary of $58,230.00 as Director at Denali Therapeutics. Learn More about Marc Tessier-Lavigne's net worth.

How old is Marc Tessier-Lavigne?

Dr. Tessier-Lavigne is currently 64 years old. There are 4 older executives and no younger executives at Denali Therapeutics. Learn More on Marc Tessier-Lavigne's age.

What is Marc Tessier-Lavigne's salary?

As the Director of Denali Therapeutics Inc., Dr. Tessier-Lavigne earns $58,230.00 per year. There are 3 executives that earn more than Dr. Tessier-Lavigne. The highest earning executive at Denali Therapeutics is Dr. Ryan J. Watts Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Marc Tessier-Lavigne's salary.

How do I contact Marc Tessier-Lavigne?

The corporate mailing address for Dr. Tessier-Lavigne and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at [email protected]. Learn More on Marc Tessier-Lavigne's contact information.

Has Marc Tessier-Lavigne been buying or selling shares of Denali Therapeutics?

Marc Tessier-Lavigne has not been actively trading shares of Denali Therapeutics over the course of the past ninety days. Most recently, Marc Tessier-Lavigne sold 20,000 shares of the business's stock in a transaction on Wednesday, November 23rd. The shares were sold at an average price of $30.48, for a transaction totalling $609,600.00. Following the completion of the sale, the director now directly owns 1,870,356 shares of the company's stock, valued at $57,008,450.88. Learn More on Marc Tessier-Lavigne's trading history.

Who are Denali Therapeutics' active insiders?

Denali Therapeutics' insider roster includes Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.

Are insiders buying or selling shares of Denali Therapeutics?

In the last twelve months, insiders at the sold shares 31 times. They sold a total of 121,653 shares worth more than $2,697,948.93. The most recent insider tranaction occured on February, 15th when Director Vicki L Sato sold 1,666 shares worth more than $30,604.42. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.

Information on this page was last updated on 2/15/2024.

Marc Tessier-Lavigne Insider Trading History at Denali Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2022Sell20,000$30.48$609,600.001,870,356View SEC Filing Icon  
11/1/2022Sell8,748$30.20$264,189.601,901,608View SEC Filing Icon  
9/28/2022Sell20,000$30.82$616,400.001,910,356View SEC Filing Icon  
8/23/2022Sell20,000$31.61$632,200.001,930,356View SEC Filing Icon  
7/25/2022Sell20,000$35.61$712,200.001,950,356View SEC Filing Icon  
3/23/2022Sell20,000$33.83$676,600.00View SEC Filing Icon  
12/30/2021Sell20,047$45.36$909,331.92View SEC Filing Icon  
12/28/2021Sell10,980$44.37$487,182.60View SEC Filing Icon  
6/7/2021Sell94,378$70.35$6,639,492.30View SEC Filing Icon  
5/24/2021Sell8,806$60.02$528,536.12View SEC Filing Icon  
5/21/2021Sell37,957$60.13$2,282,354.41View SEC Filing Icon  
4/1/2021Sell50,000$56.62$2,831,000.00View SEC Filing Icon  
6/16/2020Sell400,000$26.10$10,440,000.002,739,043View SEC Filing Icon  
See Full Table

Marc Tessier-Lavigne Buying and Selling Activity at Denali Therapeutics

This chart shows Marc Tessier-Lavigne's buying and selling at Denali Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Denali Therapeutics Company Overview

Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $20.52
Low: $20.12
High: $21.04

50 Day Range

MA: $18.60
Low: $15.83
High: $23.35

2 Week Range

Now: $20.52
Low: $15.45
High: $33.31

Volume

991,585 shs

Average Volume

1,193,573 shs

Market Capitalization

$2.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34